Bond Biosciences

Executive Summary

Bond Biosciences is a private, early-stage biopharmaceutical company headquartered in Cambridge, MA, dedicated to discovering and developing oral small-molecule therapeutics that locally bind excess metal ions in the gastrointestinal (GI) tract. By sequestering metals such as copper and iron within the gut, the company aims to treat a range of diseases driven by metal ion imbalance, including Wilson disease and hereditary hemochromatosis, while minimizing systemic side effects. Founded in 2021, the company has not disclosed specific pipeline candidates or financial details, but its GI-localized approach represents a novel, potentially safer strategy for managing metal overload disorders. Although still in preclinical or early clinical development, Bond Biosciences has the opportunity to address significant unmet needs in rare metabolic diseases.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate60% success
• Q2 2026Announcement of Series A Financing70% success